Cited by 151Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

The Differential Effects of Metformin on Markers of Endothelial Activation and Inflammation in Subjects with Impaired Glucose Tolerance: A Placebo-Controlled, Randomized Clinical Trial

Caballero, A. Enrique, Delgado, Adriano, Aguilar-Salinas, Carlos A., Herrera, Alberto Naranjo, Castillo, Jose Luis, Cabrera, Tatiana, Gomez-Perez, Francisco J., Rull, Juan A.·2004·The Journal of Clinical Endocrinology & Metabolism

DOI 10.1210/jc.2004-0019

Open this paper in CoChat — free account

Abstract

The effect of metformin (1000 mg twice a day) on markers of endothelial activation, inflammation, and coagulation was investigated in subjects with impaired glucose tolerance (IGT) in a 16-wk, randomized, placebo-controlled, double-blind study. Soluble intercellular adhesion molecule, soluble vascular cell adhesion molecule, C-reactive protein, TNFalpha, von Willebrand factor, and tissue plasminogen activator were measured at baseline and at the end of the trial. Subjects with IGT (n = 55, 14 males and 41 females), aged 48.4 +/- 9.6 yr with a body mass index of 31.4 +/- 5.6 kg/m(2), were studied. All participants followed a 1-month stabilization period in their diet and physical activity. Afterward, 29 subjects were assigned to the treatment group and 26 to the control group. A significant reduction in weight, fasting plasma glucose, soluble intercellular adhesion molecule (306 +/- 75 vs. 268 +/- 61 ng/ml, P = 0.029), soluble vascular cell adhesion molecule (595 +/- 114 vs. 508 +/- 126 ng/ml, P = 0.006), and von Willebrand factor (124 +/- 34 vs. 94 +/- 34%, P = 0.001) was seen in the treatment group, whereas tissue plasminogen activator, TNFalpha, and C-reactive protein levels did not change. No change was seen in the control group. Thus, metformin improves the plasma levels of some markers of endothelial activation and coagulation in subjects with IGT, whereas it has no effect on markers of inflammation.

Integrity signals

Registry

Crossref · 10.1210/jc.2004-0019

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
C-Reactive Protein in Healthy Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction: A Potential Role for Cytokines Originating From Adipose Tissue?
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress
Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961
Prospective Study of C-Reactive Protein and the Risk of Future Cardiovascular Events Among Apparently Healthy Women
Ridker, P. M., Buring, J. E., Shih, J., Matias, M., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.98.8.731 · Cited by 1,642

Show all 42 references

Sorted by citations

The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes
Zatterale, F., Longo, M., Naderi, J., Raciti, G. A., Desiderio, A., Miele, C., & Beguinot, F. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01607 · Cited by 1,180
Cytokine and Cytokine-Like Inflammation Markers, Endothelial Dysfunction, and Imbalanced Coagulation in Development of Diabetes and Its Complications
Goldberg, R. B. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2534 · Cited by 650
Metformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall Cells
Isoda, K., Young, J. L., Zirlik, A., MacFarlane, L. A., Tsuboi, N., Gerdes, N., Schönbeck, U., & Libby, P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000201938.78044.75 · Cited by 499
Metformin Inhibits Cytokine-Induced Nuclear Factor κB Activation Via AMP-Activated Protein Kinase Activation in Vascular Endothelial Cells
Hattori, Y., Suzuki, K., Hattori, S., & Kasai, K. (2006) · Hypertension · doi:10.1161/01.hyp.0000221429.94591.72 · Cited by 487
“1 Ci [ -(32)P]ATP, and 10 g GST-IkB (1-55) at 30°C for 20 minutes.”
MethodInfluential
Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus
Kooy, A., de Jager, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J. M., & Stehouwer, C. D. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.20 · Cited by 440
Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis
Nath, N., Khan, M., Paintlia, M. K., Hoda, M. N., & Giri, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803563 · Cited by 354
“RT-PCR was performed with SYBR Green PCR master mix (Bio-Rad) and Bio-Rad iCycler iQ PCR using the following primers: mouse IFN- sense, GCA TTC ATG AGT ATT GCC AAG and antisense, GGT GGA CCA CTC GGA TGA; TNFsense, CAT CTT CTC AAA ATT CGA GTG ACA A and antisense, TGG GAG TAG ACA AGG TAC AAC CC; IL-17 sense, CTC CAG AAG…”
Influential
Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity
Bakker, W., Eringa, E. C., Sipkema, P., & van Hinsbergh, V. W. M. (2008) · Cell and Tissue Research · doi:10.1007/s00441-008-0685-6 · Cited by 359
“Whatever the mechanism may be, the finding that an improvement in endothelial dysfunction can lead to a decrease in insulin resistance and perhaps to a reduction in the incidence of type 2 diabetes has been appreciated in the secondary analyses of some trials of medications known to improve vascular function (Egashira…”
Background
AMPK, Mitochondrial Function, and Cardiovascular Disease
Wu, S., & Zou, M.-H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144987 · Cited by 286
Repositioning metformin for cancer prevention and treatment
Quinn, B. J., Kitagawa, H., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.05.004 · Cited by 290
Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications
Pollack, R. M., Donath, M. Y., LeRoith, D., & Leibowitz, G. (2016) · Diabetes Care · doi:10.2337/dcs15-3015 · Cited by 266
“In a 12-month comparative study, exenatide demonstrated a significant decrease in hs-CRP compared with SU (47).”
BackgroundInfluential
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin
Diamanti‐Kandarakis, E., Paterakis, T., Alexandraki, K., Piperi, C., Aessopos, A., Katsikis, I., Katsilambros, N. L., Kreatsas, G., & Panidis, D. (2006) · Human Reproduction · doi:10.1093/humrep/del003 · Cited by 262
“However, the differential effect of metformin on plasma concentrations of sICAM-1 and sE-selectin cannot be explained in this study; it is possible that longer duration of treatment is required, as it has been shown in PCOS and other IR populations (Morin-Papunen et al., 1998; UKPDS, 1998; Caballero, 2003; Grant, 2003…”
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction
Brownfoot, F. C., Hastie, R., Hannan, N. J., Cannon, P., Tuohey, L., Parry, L. J., Senadheera, S., Illanes, S. E., Kaitu’u-Lino, T. J., & Tong, S. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.12.019 · Cited by 222
The Cellular and Molecular Basis of Translational Immunometabolism
Norata, G. D., Caligiuri, G., Chavakis, T., Matarese, G., Netea, M. G., Nicoletti, A., O'Neill, L. A. J., & Marelli‐Berg, F. M. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.023 · Cited by 197
“Metformin has effects beyond those on glucose metabolism and decreases plasma inflammatory markers, including soluble intercellular adhesion molecule, vascular cell adhesion molecule 1, macrophage migration inhibitory factor, and C-reactive protein (Caballero et al., 2004; Dandona et al., 2004).”
Background
Metformin Suppresses Lipopolysaccharide (LPS)-induced Inflammatory Response in Murine Macrophages via Activating Transcription Factor-3 (ATF-3) Induction
Kim, J., Kwak, H. J., Cha, J.-Y., Jeong, Y.-S., Rhee, S. D., Kim, K. R., & Cheon, H. G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.577908 · Cited by 197
“Notably, clinical outcomes suggest that metformin may alter inflammation independently of its effect on glycemic control (13, 14).”
Background
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Goldfine, A. B., & Shoelson, S. E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88884 · Cited by 176
“The antiinflammatory actions of metformin appear to be independent of glycemia (58, 78, 79) and are most prominent in immune cells and vascular tissues (53, 54, 74, 80, 81).”
Metformin restores endothelial function in aorta of diabetic rats
Sena, C. M., Matafome, P. N., Louro, T. M., Nunes, E., Fernandes, R., & Seiça, R. M. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01230.x · Cited by 168
“Clinical studies further suggest that metformin may alter inflammation as determined by decreased inflammatory markers in plasma, including soluble intercellular adhesion molecule, vascular cell adhesion molecule-1, nuclear factor k-B and C-reactive protein in some cases of polycystic ovary syndrome, indicating modula…”
Background
Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis
Custodero, C., Mankowski, R. T., Lee, S. A., Chen, Z., Wu, S. S., Manini, T. M., Hincapie-Echeverri, J., Sabbà, C., Beavers, D. P., Cauley, J. A., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.004 · Cited by 169
Paradoxic effects of metformin on endothelial cells and angiogenesis
Dallaglio, K., Bruno, A., Cantelmo, A. R., Esposito, A. I., Ruggiero, L., Orecchioni, S., Calleri, A., Bertolini, F., Pfeffer, U., Noonan, D. M., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu001 · Cited by 146
Metformin: Effects on Micro and Macrovascular Complications in Type 2 Diabetes
Bailey, C. J. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6092-0 · Cited by 138
“Metformin has been shown to reduce C-reactive protein concentrations in type 2 diabetes, impaired glucose tolerance and polycystic ovary syndrome independently of glycaemic control [58–60], and possibly reduce levels of other pro-inflammatory cytokines or reduce cytokineinduced activation of the transcription factor n…”
Background
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial
Baptista, T., Rangel, N., Fernández, V., Carrizo, E., Fakih, Y. E., Uzcátegui, E., Galeazzi, T., Gutiérrez, M. A. M., Servigna, M., Dávila, A., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.029 · Cited by 138
Effects of PGC-1α on TNF-α–Induced MCP-1 and VCAM-1 Expression and NF-κB Activation in Human Aortic Smooth Muscle and Endothelial Cells
Kim, H., Park, K., Yoo, E.-K., Kim, Y.-H., Kim, Y.-N., Kim, H., Kim, H. T., Park, J., Lee, K.-U., Jang, W. G., et al. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.1456 · Cited by 137
Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial
Pradhan, A. D., Everett, B. M., Cook, N. R., Rifai, N., & Ridker, P. M. (2009) · JAMA · doi:10.1001/jama.2009.1347 · Cited by 117
Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country. A randomized control trial
Ainuddin, J., Karim, N., Hasan, A. A., & Naqvi, S. A. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.10.001 · Cited by 118
“[7] Casallero AE, Delgado A, Aguilar-Salinas CA, Herrera AN, Castello JL, Labrera T, et al.”
Background
Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function
Ding, Y., Zhou, Y., Ling, P., Feng, X., Luo, S., Zheng, X., Little, P. J., Xu, S., & Weng, J. (2021) · Theranostics · doi:10.7150/thno.64706 · Cited by 121
“Furthermore, metformin reduces the inflammatory biomarkers, such as vWF, sVCAM1, and sICAM1, among volunteers with impaired glucose tolerance [172].”
Background
The effect of metformin on measurements of insulin sensitivity and β cell response in 18 horses and ponies with insulin resistance
Durham, A. E., Rendle, D. I., & Newton, J. R. (2008) · Equine Veterinary Journal · doi:10.2746/042516408x273648 · Cited by 117
Endothelial dysfunction, inflammation, and insulin resistance: A focus on subjects at risk for type 2 diabetes
Caballero, A. E. (2004) · Current Diabetes Reports · doi:10.1007/s11892-004-0074-9 · Cited by 114
Antihyperglycemic, antihyperlipidemic, anti-inflammatory and adenosine deaminase–lowering effects of garlic in patients with type 2 diabetes mellitus with obesity
Kumar, R., Chhatwal, S., Arora, S., Sharma, S., Singh, J., Singh, N., Bhandari, V., & Khurana, A. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s38888 · Cited by 113
“Caballero et al, 16 in their study on the differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance, observed that metformin improved the plasma levels of some markers of endothelial activation and coagulation in subjects with impaired glucose t…”
Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy
Ainuddin, J. A., Karim, N., Zaheer, S., Ali, S. S., & Hasan, A. A. (2015) · Journal of Diabetes Research · doi:10.1155/2015/325851 · Cited by 108
Diabetes in the hispanic or latino population: Genes, environment, culture, and more
Caballero, A. E. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0012-5 · Cited by 104
The Effect of Metformin on Insulin Resistance and Exercise Parameters in Patients with Heart Failure
Wong, A., Symon, R., AlZadjali, M. A., Ang, D. S. C., Ogston, S. A., Choy, A. M., Petrie, J. R., Struthers, A. D., & Lang, C. C. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs106 · Cited by 104
“The dose and duration of metformin therapy was based on a previous study in patients with impaired glucose tolerance, which showed that this dose regimen was well tolerated and had a beneficial effect on endothelial function.(13) The metformin study drug was commenced at 500 mg b.”
Method
Metformin reduces abortion in pregnant women with polycystic ovary syndrome
Khattab, S., Mohsen, I. A., Foutouh, I. A., Ramadan, A. R., Moaz, M., & Al-Inany, H. G. (2006) · Gynecological Endocrinology · doi:10.1080/09513590601010508 · Cited by 98
Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome?
Hughes, R. C. E., & Rowan, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01750.x · Cited by 98
Treating prediabetes with metformin: systematic review and meta-analysis.
Lily, M., Lilly, M., & Godwin, M. S. (2009) · PubMed Central · Cited by 97
Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview
Correia, S. C., Carvalho, C., Santos, M. S., Seiça, R. M. F., Oliveira, C. R., & Moreira, P. I. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708786369546 · Cited by 98
“Metformin also reduces the levels of soluble intercellular cell-adhesion molecules (ICAM-1) and soluble vascular cell-adhesion molecules (VCAM-1) in subjects with impaired glucose tolerance [140].”
Background
METFORMIN, ARTERIAL FUNCTION, INTIMA–MEDIA THICKNESS AND NITROXIDATION IN METABOLIC SYNDROME: THE MEFISTO STUDY
Meaney, E., Vela, A., Samaniego, V., Meaney, A., Asbún, J., Zempoalteca, J. C., Elisa, Z. N., Emma, M. N., Guzman, M., Hicks, J. J., et al. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.04920.x · Cited by 89
“of endothelial cell activation, whereas levels of inflammatory markers remain unchanged.(21) Metformin has also been shown to reduce oxidative stress in animal experiments,(72) but this effect has not been properly investigated in patients with MS.”
BackgroundInfluential
Metabolic and Vascular Abnormalities in Subjects at Risk for Type 2 Diabetes: The Early Start of a Dangerous Situation
Caballero, A. E. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.03.013 · Cited by 82
Metformin: The hidden chronicles of a magic drug
Mahmood, K., Naeem, M., & Rahimnajjad, N. A. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.10.011 · Cited by 80
Adipose Tissue Immunomodulation: A Novel Therapeutic Approach in Cardiovascular and Metabolic Diseases
AlZaim, I., Hammoud, S. H., Al-Koussa, H., Ghazi, A., Eid, A. H., & EL‐Yazbi, A. F. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.602088 · Cited by 78
Effects of Simvastatin and Metformin on Inflammation and Insulin Resistance in Individuals with Mild Metabolic Syndrome
Bulc??o, C., Ribeiro‐Filho, F. F., Sañudo, A., & Ferreira, S. G. R. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707030-00007 · Cited by 71
Effects of metformin on blood pressure in nondiabetic patients
Zhou, L., Liu, H., Wen, X., Peng, Y., Tian, Y., & Zhao, L. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001119 · Cited by 71
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
Madsen, K. S., Chi, Y., Metzendorf, M.-I., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008558.pub2 · Cited by 70
Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure
Schernthaner, G., Brand, K. M. G., & Bailey, C. J. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155160 · Cited by 72
Review: Metformin: Potential benefits and use in chronic kidney disease
Pilmore, H. (2010) · Nephrology · doi:10.1111/j.1440-1797.2010.01328.x · Cited by 69
Rosuvastatina y metformina reducen la inflamación y el estrés oxidativo en pacientes con hipertensión y dislipemia
Gómez‐García, A., Torres, G. M., Ortega-Pierres, L. E., Rodríguez-Ayala, E., & Álvarez-Aguilar, C. (2007) · Revista Española de Cardiología · doi:10.1157/13113929 · Cited by 66
Cardioprotective effect of metformin in lipopolysaccharide-induced sepsis via suppression of toll-like receptor 4 (TLR4) in heart
Vaez, H., Rameshrad, M., Najafi, M., Barar, J., Barzegari, A., & Garjani, A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.12.030 · Cited by 66
Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment
Jakubowska, J., Bohdanowicz-Pawlak, A., Milewicz, A., Szymczak, J., Bednarek-Tupikowska, G., & Demissie, M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590802128968 · Cited by 65
“There was only the work of Caballero and colleagues, where men and women with impaired glucose tolerance were treated with metformin [33].”
Background
The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD?
Diamant, M., & Tushuizen, M. E. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0061-4 · Cited by 64
“In spite of these favorable effects in vitro, the effects of metformin on inflammation and (markers of) ED in humans are controversial [ 60 ,61].”
Background
Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4
Song, J., Ren, P., Zhang, L., Wang, X. L., Chen, L., & Shen, Y. H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.086 · Cited by 62
AMPKα2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6
Gongol, B., Marin, T., Peng, I.-C., Woo, B., Martin, M., King, S., Sun, W., Johnson, D. A., Chien, S., & Shyy, J. Y.-J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222051110 · Cited by 61
“Metformin has been shown to improve an array of inflammatory events, including diabetes mellitus and postsurgical endotoxin–induced inflammation (38, 39).”
Background
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
Hemmingsen, B., Sonne, D. P., Metzendorf, M., & Richter, B. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012151.pub2 · Cited by 76
Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model – the Zucker diabetic rat
Forcheron, F., Basset, A., Abdallah, P., del Carmine, P., Gadot, N., & Beylot, M. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-16 · Cited by 58
“This is surprising since, although metformin did not decrease circulating levels of C reactive protein and cell adhesion molecules in subjects with impaired glucose tolerance [49], it reduced the TNFα-induced activation of NFκB and secretion of VCAM-1 and MCP-1 in vascular endothelial cells [50].”
Background
Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated hemoglobin (HbA1c) in patients with prediabetes and type 2 diabetes
Klisic, A. N., Kavarić, N., Stanišić, V., Vujčić, S., Spasojević‐Kalimanovska, V., Ninić, A., & Kotur‐Stevuljević, J. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.87541 · Cited by 56
“Moreover, metformin was shown to decrease levels of endocan and some endothelial markers [11, 29], whereas antilipemic agents exert beneficial effects on endothelial cells, and consequently lower endocan levels, also [30].”
Background
Antidepressant Medicine Use and Risk of Developing Diabetes During the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study
Rubin, R. R., Ma, Y., Peyrot, M., Marrero, D. G., Price, D. W., Barrett-Connor, E., Knowler, W. C., & for the Diabetes Prevention Program Research Group (2010) · Diabetes Care · doi:10.2337/dc10-1033 · Cited by 71
“Metformin also appears to ameliorate inflammation (8), and inflammatory markers appear to be associated with depression (9).”
Background
Venous thrombosis is associated with hyperglycemia at diagnosis: a case–control study
Hermanides, J., Cohn, D. M., DeVries, J. H., Kamphuisen, P. W., Huijgen, R., Meijers, J. C. M., Hoekstra, J. B. L., & Buller, H. R. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03442.x · Cited by 53
Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial
Gómez-Díaz, R. A., Talavera, J. O., Canché-Pool, E. B., Ortiz-Navarrete, V. F., Solórzano‐Santos, F., Mondragón-González, R., Valladares‐Salgado, A., Cruz, M., Aguilar-Salinas, C. A., & Wacher, N. H. (2012) · Metabolism · doi:10.1016/j.metabol.2012.02.003 · Cited by 53
“[49] Caballero AE, Delgado A, Aguilar-Salinas CA, et al.”
Background
Effect of Glycemic Regulation on Endocan Levels in Patients With Diabetes
Arman, Y., Akpınar, T. S., Köse, M., Emet, S., Yürüyen, G., Akarsu, M., Özcan, M., Yeğit, O. O., Çakmak, R., Altun, Ö., et al. (2015) · Angiology · doi:10.1177/0003319715585664 · Cited by 50
Metformin reduces hepatic resistance and portal pressure in cirrhotic rats
Tripathi, D. M., Erice, E., Lafoz, E., García‐Calderó, H., Sarin, S. K., Bosch, J., Gracia‐Sancho, J., & García‐Pagán, J. C. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00010.2015 · Cited by 47
Role of postprandial hyperglycemia in cardiovascular disease
Fava, S. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.6.859 · Cited by 47
Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients
Kiyici, S. K., Ersoy, C., Kaderlï, A. A., Fazlıoğlu, M., Budak, F., Duran, C., Gül, Ö. Ö., Sığırlı, D., Baran, İ., Tuncel, E., et al. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.07.004 · Cited by 46
Metformin Inhibits Chemokine Expression Through the AMPK/NF-κB Signaling Pathway
Ye, J., Zhu, N., Sun, R., Liao, W., Fan, S., Shi, F., Lin, H., Jiang, S., & Ying, Y. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0061 · Cited by 51
Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
Levy, J., Cobas, R. A., & Gomes, M. B. (2010) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-2-16 · Cited by 44
AMPK activation by metformin inhibits local innate immune responses in the isolated rat heart by suppression of TLR 4-related pathway
Vaez, H., Najafi, M., Rameshrad, M., Toutounchi, N. S., Garjani, M., Barar, J., & Garjani, A. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.10.002 · Cited by 43
Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein
Dandona, P. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.3.333 · Cited by 42
Metformin: time to review its role and safety in chronic kidney disease
Tanner, C., Wang, G., Liu, N., Andrikopoulos, S., Zajac, J. D., & Ekinci, E. I. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50239 · Cited by 43
High fat-induced inflammation in vascular endothelium can be improved by Abelmoschus esculentus and metformin via increasing the expressions of miR-146a and miR-155
Gou, L., Liu, G., Ma, R., Regmi, A., Zeng, T., Zheng, J., Zhong, X., & Chen, L. (2020) · Nutrition & Metabolism · doi:10.1186/s12986-020-00459-7 · Cited by 38
Metformin suppresses pro-inflammatory cytokines in vitreous of diabetes patients and human retinal vascular endothelium
Li, Y., Gappy, S. S., Liu, X., Sassalos, T. M., Zhou, T., Hsu, A., Zhang, A., Edwards, P. A., Gao, H., & Qiao, X. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268451 · Cited by 40
“Another study found that short-term metformin treatment (16 weeks) resulted in a substantial drop in plasma sICAM-1, but not in t-PA, TNFα, or CRP [36].”
Background
Comparison of the Effects of Pioglitazone and Metformin on Insulin Resistance and Hormonal Markers in Patients with Impaired Glucose Tolerance and Early Diabetes
EGUCHI, K., Tomizawa, H., Ishikawa, J., Hoshide, S., Numao, T., Fukuda, T., Shimada, K., & Kario, K. (2007) · Hypertension Research · doi:10.1291/hypres.30.23 · Cited by 37
“On the other hand, there is growing evidence that metformin improves insulin resistance, cardiovascular risk factors, and the development of diabetes mellitus (10, 11).”
Background
Feto-maternal outcomes and Glycemic control in Metforminversus insulin treated Gestational Diabetics
Arshad, R., Khanam, S., SHAIKH, D. F., & Karim, D. N. (2017) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.335.13286 · Cited by 37
Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor Behind the Scene
Anwar, M. A., Kheir, W. A., Eid, S., Fares, J., Liu, X., Eid, A. H., & Eid, A. A. (2014) · Journal of Cancer · doi:10.7150/jca.9726 · Cited by 35
“Metformin, a cationic (hydrophilic base) drug, exerts its pleiotropic pharmacological effects beyond those of metabolic control (14), and includes favorable anti-inflammatory outcomes (15, 16).”
Background
Metformin Inhibits Porphyromonasgingivalis Lipopolysaccharide‐Influenced Inflammatory Response in Human Gingival Fibroblasts via Regulating Activating Transcription Factor‐3 Expression
Kang, W., Wang, T., Hu, Z., Liu, F., Sun, Y., & Ge, S. (2017) · Journal of Periodontology · doi:10.1902/jop.2017.170168 · Cited by 36
Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: An Asian-Pacific perspective
Chan, J. C. N., Deerochanawong, C., Shera, A. S., Yoon, K., Adam, J. M. F., Binh, T. V., Chan, S.-P., Fernando, R. E., Horn, L. C., Khue, N. T., et al. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.06.023 · Cited by 35
The role of inflammation in diabetic cardiomyopathy
Reis, F., Nunes, Soares, & Pereira (2012) · International Journal of Interferon Cytokine and Mediator Research · doi:10.2147/ijicmr.s21679 · Cited by 36
“106 However, the risk of lactic acidosis caused by metformin may be a contraindication for its use in diabetic patients with heart failure.”
Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects
Rizza, S., Cardellini, M., Porzio, O., Pecchioli, C., Savo, A., Cardolini, I., Senese, N., Lauro, D., Sbraccia, P., Lauro, R., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.12.021 · Cited by 35
“recently associated with reduction in all causes of mortality compared with metformin [3] and rosiglitazone [4].”
Background
Bonus Effects of Antidiabetic Drugs: Possible Beneficial Effects on Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis
Pereira, C. A., Carneiro, F. S., Matsumoto, T., & Tostes, R. C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13054 · Cited by 34
Effect of Metformin on Circulating Levels of Inflammatory Markers in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Karbalaee‐Hasani, A., Khadive, T., Eskandari, M., Shahidi, S., Mosavi, M., Nejadebrahimi, Z., Khalkhali, L., Sangdari, A., Mohammadi, D., Soltani, A., et al. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020985303 · Cited by 34
Immunometabolic cross-talk in the inflamed heart
Marelli‐Berg, F. M., & Aksentijević, D. (2019) · Cell Stress · doi:10.15698/cst2019.08.194 · Cited by 36
“Abbreviatons: AMPK – AMP-activated protein kinase, ATP – adenosine triphosphate, CAD – coronary artery disease, CK – creatine kinase, CMR – cardiac magnetic resonance, CRP – C-reactive protein, DAG – diacylglycerol, DC – dendritic cell, DCM – dilated cardiomyopathy, ERR – estrogen-related receptor, ETC – electron tran…”
BackgroundInfluential
Diabetes Mellitus-Associated Atherosclerosis
Calkin, A. C., & Allen, T. J. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606010-00003 · Cited by 31
The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials
Haber, R., Zarzour, F., Ghezzawi, M., Saadeh, N., Bacha, D. S., Jebbawi, L. A., Chakhtoura, M., & Mantzoros, C. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15501 · Cited by 35
Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials
Weng, S., Luo, Y., Zhang, Z., Su, X., & Peng, D. (2020) · Endocrine · doi:10.1007/s12020-020-02190-y · Cited by 31
An investigation into the pleiotropic activity of metformin. A glimpse of haemostasis
Markowicz-Piasecka, M., Sadkowska, A., Huttunen, K. M., Podsiedlik, M., Mikiciuk‐Olasik, E., & Sikora, J. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.172984 · Cited by 31
Effect of metformin treatment on endometrial vascular indices in anovulatory obese/overweight women with polycystic ovarian syndrome using three‐dimensional power doppler ultrasonography
Mohsen, I. A., ElKattan, E. A., Nabil, H., & Khattab, S. (2012) · Journal of Clinical Ultrasound · doi:10.1002/jcu.22006 · Cited by 26
“Furthermore, metformin administration improves endothelial function in women with PCOS as it improves markers of endothelial activation and coagulation, eg, soluble intercellular adhesion molecule, plasma plasminogen activator inhibitor-1, soluble vascular adhesion molecule, plasma endothelin-1, and E-selectin.(28,31,…”
Background
Translation of mechanistic advances in preeclampsia to the clinic: Long and winding road
Thadhani, R., Cerdeira, A. S., & Karumanchi, S. A. (2024) · The FASEB Journal · doi:10.1096/fj.202301808r · Cited by 27
Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus
Hsieh, C., He, C.-T., Lee, C.-H., Wu, L., & Hung, Y. (2007) · Metabolism · doi:10.1016/j.metabol.2007.03.018 · Cited by 25
Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach
Khattab, S., Foutouh, I. A., Mohesn, I. A., Metwally, M. A., & Moaz, M. (2006) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60614-1 · Cited by 24
Short-Term Treatment with Metformin Improves the Cardiovascular Risk Profile in First-Degree Relatives of Subjects with Type 2 Diabetes Mellitus who have a Metabolic Syndrome and Normal Glucose Tolerance without Changes in C-Reactive Protein or Fibrinogen
de Lima, L. M. A., Wiernsperger, N. F., Kraemer‐Aguiar, L. G., & Bouskela, E. (2009) · Clinics · doi:10.1590/s1807-59322009000500008 · Cited by 23
“Age (years) 37 [32-42] 40 [33.”
Metformin-attenuated sepsis-induced oxidative damages: a novel role for metformin.
Ghavimi, H., Sheidaei, S., Vaez, H., Zolali, E., Asgharian, P., & Hamishehkar, H. (2018) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2018.24610.6126 · Cited by 19
“Based on the results obtained in different studies, metformin has been proven to be beneficial against inflammatory conditions (19, 43).”
Result
Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease
Kruszelnicka, O., Chyrchel, B., Golay, A., & Surdacki, A. (2015) · Amino Acids · doi:10.1007/s00726-015-1976-3 · Cited by 19
Ethinylestradiol30μg-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome?
Ilie, I. R. P., Marian, I., Mocan, T., Ilie, R., MOCAN, L. C., Duncea, I., & Pepene, C. E. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-9 · Cited by 19
Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone
Yener, S., Çömlekçi, A., Akıncı, B., Akan, P., Demir, T., Bayraktar, F., & Yeşil, S. (2008) · HORMONES · doi:10.14310/horm.2002.1111039 · Cited by 18
The role of autoimmunity in the pathophysiology of type 2 diabetes: Looking at the other side of the moon
Koufakis, T., Dimitriadis, G., Metallidis, S., Zebekakis, P. E., & Kotsa, K. (2021) · Obesity Reviews · doi:10.1111/obr.13231 · Cited by 19
“Metformin has been shown to modestly decrease CRP concentrations in individuals with impaired glucose tolerance(106) but had no significant effect on TNF-α levels.(107) It also reduced the production of the proinflammatory and proapoptotic protein TXNIP in rodent pancreas and liver.”
Background
Clinical research Advantage of adjunct metformin and insulin therapy in the management of glycemia in critically ill patients. Evidence for nonoccurrence of lactic acidosis and needing to parenteral metformin
Mojtahedzadeh, M., Rouini, M. R., Kajbaf, F., Najafi, A., Ansari, G., Baradari, A. G., Mofid, A. R., & Abdollahi, M. R. (2008) · Archives of Medical Science · Cited by 17
Similarities and Distinctions in the Effects of Metformin and Carbon Monoxide in Immunometabolism.
Park, J., Joe, Y., Ryter, S. W., Surh, Y., & Chung, H. (2019) · PubMed · doi:10.14348/molcells.2019.0016 · Cited by 16
“Also, metformin has been shown to decrease various proinflammatory markers, including soluble intercellular adhesion molecule, vascular cell adhesion molecule 1, macrophage migration inhibitory factor and C-reactive protein (Caballero et al., 2004; Dandona et al., 2004).”
Background
Traffic exposure in a population with high prevalence type 2 diabetes – Do medications influence concentrations of C-reactive protein?
Rioux, C. L., Tucker, K. L., Brugge, D., Gute, D. M., & Mwamburi, M. (2011) · Environmental Pollution · doi:10.1016/j.envpol.2010.12.025 · Cited by 15
“…inflammatory markers including CRP have been equivocal, with some studies reporting decreases with use of metformin (Chu et al., 2002; DPPRG, 2005; Caballero et al., 2004) and others reporting no significant effects (De Jager et al., 2005; Pradhan et al., 2001) Glitazones, taken by 78…”
Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients
Imai, C., Saito, M., Mochizuki, K., Fuchigami, M., Goda, T., & Osonoi, T. (2014) · Metabolism · doi:10.1016/j.metabol.2013.12.014 · Cited by 16
“[24] Caballero AE, Delgado A, Aguilar-Salinas CA, et al.”
Background
Clinical Significance of High-Sensitivity C-Reactive Protein in Cardiovascular Disease
Conen, D., & Ridker, P. M. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.2.229 · Cited by 16
Novel therapeutic and diagnostic approaches for preeclampsia
Vatish, M., Powys, V. R., & Cerdeira, A. S. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000870 · Cited by 13
Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes
Perriello, G., Pampanelli, S., Brunetti, P., Pietro, C. D., & Mariz, S. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.044 · Cited by 14
“Metformin has also been shown to reduce vWf levels significantly in obese, non-diabetic patients(27) and in those with impaired glucose tolerance.(28) Rosiglitazone has been shown to improve a number of circulating procoagulation markers when given as monotherapy.”
Background
The Effects of Metformin on Weight Loss, Cardiovascular Health, and Longevity
Pillai, A. A., Melo, L., Frishman, W. H., & Aronow, W. S. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000832 · Cited by 17
Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease
Miller, W. M., Janosz, K. E. N., Yanez, J., & McCullough, P. A. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.4.743 · Cited by 10

Authors: Caballero, A. E., Delgado, A., Aguilar-Salinas, C. A., Herrera, A. N., Castillo, J. L., Cabrera, T., Gomez-Perez, F. J., & Rull, J. A.
Affiliations: Joslin Diabetes Center (US)
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
Corresponding author: Aguilar-Salinas, Carlos A.
ORCID: Caballero, A. Enrique
Delgado, Adriano
Aguilar-Salinas, Carlos A.
Gomez-Perez, Francisco J.
Rull, Juan A.
Venue: The Journal of Clinical Endocrinology & Metabolism
Publisher: The Endocrine Society
Published: 2004-08
Volume: 89
Issue: 8
Pages: 3943-3948
ISSN: 0021-972X (ISSN-L)
1945-7197
DOI: 10.1210/jc.2004-0019
OpenAlex: W2028079896
Cited by: 151
References: 42
Citations by year: 2026: 2 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 9 · 2021: 4 · 2020: 9 · 2019: 8 · 2018: 5 · 2017: 4 · 2016: 6 · 2015: 7 · 2014: 8 · 2013: 6 · 2012: 10
FWCI: 6.82
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords: metformin, impaired glucose tolerance, endothelial activation, inflammation, coagulation, soluble intercellular adhesion molecule, soluble vascular cell adhesion molecule, von Willebrand factor, tissue plasminogen activator, C-reactive protein, TNF-α, weight loss, prediabetes
MeSH terms: Adult, Blood Glucose, Double-Blind Method, Endothelium, Vascular, Fasting, Female, Homeostasis, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Models, Biological, Solubility, Vasculitis, von Willebrand Factor, Biomarkers, Weight Loss, Cell Adhesion Molecules, Glucose Intolerance, Vascular Cell Adhesion Molecule-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Differential Effects of Metformin on Markers of Endothelial Activation and Inflammation in Subjects with Impaired Glucose Tolerance: A Placebo-Controlled, Randomized Clinical Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks